EDISON, NJ (TIP): The Global Indian Trade and Cultural Council USA (GITCC) is shaping into a Global Platform for Asian Indians to global market, will implement in September 2023, the first US-India Business and Healthcare Summit to bring global healthcare recognition to the region. It will help define India as a hub of innovation for training and research infrastructure in bringing to the region healthcare excellence through knowledge and technology transfers between the U.S. and India. US-India Healthcare Summit will increase commercial ties to implement enterprises tapping U.S.- India expertise to Indian pharmaceutical market expected to grow to US$ 100 billion by 2025.

Mr. H S Panaser President GITCC started meeting the leaders in the healthcare segment in India. He initiated his visit with Dr. Rahul Gupta the US White House Director of National Drug Policy.  They Met the Chief Minister of Karnataka Sh. Basavaraj Bommai and Dr C N Ashwath Narayan, Minister for IT & BT, Science & Technology, Higher Education, Skill Development, Entrepreneurship & Livelihood, Government of Karnataka to deliberate on new avenues in anti-narcotics and manufacturing of medication to treat drug dependence for US and other markets in the backdrop of firms globally pursuing the China-Plus-One strategy.

Collaborative engagements in the areas of enforcement, regulatory frameworks, transparency through effective IT Systems, building of robust frameworks for the growth of the pharmaceutical industry were discussed. As per the New Education Policy (NEP), the government unveiled its ambitious ‘Twinning Programme’ in 2021. A first-of-its-kind in India, it aims to internationalize higher education. Cooperation in student exchange programs, educational twinning programs, curriculum building, upskilling and job growth in leading edge programs in Healthcare, Biotech, Tele-health, IT and Data Security were also discussed in detail.

A 2021 World Drug Report released by the United Nations Office on Drugs and Crime (UNODC) indicated that over 36 million people have suffered from substance use disorders (SUD). According to Global Data’s Clinical Trial Database, nearly 80% of clinical trials are being sponsored by academic institutions, the pharmaceutical industry is lagging behind in the clinical arena of addiction treatments.

Post the discussion, Dr CN Ashwath Narayan said, “India and the USA are already working on bolstering the India-US counter-narcotics agreement as India assumes G20 presidency from December this year. The Government of Karnataka is exploring partnerships with the USA to continue to strengthen this dialogue. Further, we will share best practices for monitoring the use of unregulated chemicals in drug manufacturing. We look forward to interacting with the White House and delegates from the US soon.”

With its robust ecosystem of IT, pharma R&D centers, manufacturing, academic institutions, and leading technology companies, Karnataka is the only state in India that maintains a country-to-state relationship akin to country-to-country bilateral relations

We were humbled to be invited by KDPMA, the Apex body of the Pharmaceutical Manufacturers in Karnataka with members from Small, Medium, and Large-Scale Units, Government Enterprises and Multinationals, to an event “Meet and Greet,” Dr. Rahul Gupta on 14th November 2022. Mr Harish Jain, President KDPMA and Mr. Suresh Khanna of IPA, welcomed the attendees and the GITCCs team consisting of the chief Guest Dr Rahul Gupta and Mr. H S Panaser A wide range of topics were addressed including API, Generic, Anti-Narcotics Medical Devices, AI and ML in Healthcare and Pharmacovigilance and Cyber Security. We talked about working as “We” not “I” on a global platform, The first such initiative of all coming to one platform as top manufacturers, MSMEs and SMEs will participate in the First US India Healthcare Summit 2023 in NY to be organized by Global Indian Trade and Cultural Council USA

Dr. Rahul spoke at the event, emphasizing the severity of Drug menace and advocated a campaign of Corporate Social Responsibility initiative as in being initiated by GITCC and other organizations in the US. Mr. Panaser emphasizing on deepening US India business relations and on the Drug menace. Dr Gupta appreciated the CSR initiative as in being initiated by GITCC It was humbling to have Dr. H. G. Koshia, Commissioner FDAC, Gujarat as an honorable speaker presenting the overview and economic snapshot, the regulatory framework along with other drivers for growth in Pharmaceuticals and Educational infrastructure of India and Gujarat and the US India initiations.

The event was attended by Food and Drug administration officials, ‘ business leaders’ bureaucrats and pharmaceutical manufacturers from Karnataka, Telangana, and Gujarat. Our special thanks to KDPMA, its President Mr. H Jain and Mr. S. Khanna for organizing this event. Our special thanks to Mr. A Surana of Micro Labs and Mr. U K Singh of Kumar Organics for sponsoring this event.